Themis Medicare Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Themis Medicare.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 17.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Investor Optimism Abounds Themis Medicare Limited (NSE:THEMISMED) But Growth Is Lacking
Jan 21
What Themis Medicare Limited's (NSE:THEMISMED) 42% Share Price Gain Is Not Telling You
Dec 27Themis Medicare (NSE:THEMISMED) Takes On Some Risk With Its Use Of Debt
Dec 01Themis Medicare (NSE:THEMISMED) Has Affirmed Its Dividend Of ₹5.00
Aug 18Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00
Aug 04Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00
Jul 18We Think Themis Medicare (NSE:THEMISMED) Is Taking Some Risk With Its Debt
Jul 08Themis Medicare (NSE:THEMISMED) Is Due To Pay A Dividend Of ₹5.00
May 18Themis Medicare (NSE:THEMISMED) Seems To Use Debt Quite Sensibly
Dec 21Themis Medicare (NSE:THEMISMED) Has Announced That It Will Be Increasing Its Dividend To ₹5.00
Aug 28Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹5.00
Aug 08Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's
Jul 21Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's
May 27Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?
May 12Calculating The Fair Value Of Themis Medicare Limited (NSE:THEMISMED)
Nov 09Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?
Oct 26Increases to Themis Medicare Limited's (NSE:THEMISMED) CEO Compensation Might Cool off for now
Sep 11Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹4.30
Aug 16Do Themis Medicare's (NSE:THEMISMED) Earnings Warrant Your Attention?
Jul 09In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Themis Medicare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 4,203 | 530 | 187 | 384 | N/A |
| 6/30/2024 | 4,081 | 500 | N/A | N/A | N/A |
| 3/31/2024 | 3,818 | 435 | 37 | 221 | N/A |
| 12/31/2023 | 3,640 | 453 | N/A | N/A | N/A |
| 9/30/2023 | 3,703 | 512 | -89 | 179 | N/A |
| 6/30/2023 | 3,565 | 577 | N/A | N/A | N/A |
| 3/31/2023 | 3,543 | 569 | -127 | 161 | N/A |
| 12/31/2022 | 3,540 | 584 | N/A | N/A | N/A |
| 9/30/2022 | 3,602 | 576 | -72 | 180 | N/A |
| 6/30/2022 | 3,765 | 591 | N/A | N/A | N/A |
| 3/31/2022 | 3,946 | 729 | 138 | 344 | N/A |
| 12/31/2021 | 3,766 | 710 | N/A | N/A | N/A |
| 9/30/2021 | 3,472 | 703 | 395 | 570 | N/A |
| 6/30/2021 | 2,947 | 591 | N/A | N/A | N/A |
| 3/31/2021 | 2,307 | 357 | 389 | 570 | N/A |
| 12/31/2020 | 2,151 | 349 | N/A | N/A | N/A |
| 9/30/2020 | 2,033 | 338 | 131 | 263 | N/A |
| 6/30/2020 | 1,987 | 274 | N/A | N/A | N/A |
| 3/31/2020 | 2,016 | 248 | -55 | 3 | N/A |
| 12/31/2019 | 1,911 | 61 | N/A | N/A | N/A |
| 9/30/2019 | 1,855 | -45 | 99 | 124 | N/A |
| 6/30/2019 | 1,846 | -64 | N/A | N/A | N/A |
| 3/31/2019 | 1,838 | -107 | 53 | 109 | N/A |
| 12/31/2018 | 2,002 | 54 | N/A | N/A | N/A |
| 9/30/2018 | 2,022 | 78 | N/A | N/A | N/A |
| 6/30/2018 | 2,063 | 101 | N/A | N/A | N/A |
| 3/31/2018 | 2,095 | 113 | N/A | 79 | N/A |
| 12/31/2017 | 2,354 | 105 | N/A | N/A | N/A |
| 9/30/2017 | 2,399 | 143 | N/A | N/A | N/A |
| 6/30/2017 | 2,323 | 142 | N/A | N/A | N/A |
| 3/31/2017 | 2,167 | 160 | N/A | -15 | N/A |
| 12/31/2016 | 2,438 | 211 | N/A | N/A | N/A |
| 9/30/2016 | 2,368 | 212 | N/A | N/A | N/A |
| 6/30/2016 | 2,404 | 208 | N/A | N/A | N/A |
| 3/31/2016 | 2,324 | 163 | N/A | 258 | N/A |
| 12/31/2015 | 2,287 | 155 | N/A | N/A | N/A |
| 9/30/2015 | 2,227 | 142 | N/A | N/A | N/A |
| 6/30/2015 | 2,022 | 71 | N/A | N/A | N/A |
| 3/31/2015 | 2,019 | 62 | N/A | 191 | N/A |
| 3/31/2014 | 1,951 | 27 | N/A | 83 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if THEMISMED's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if THEMISMED's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if THEMISMED's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if THEMISMED's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if THEMISMED's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if THEMISMED's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 13:58 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Themis Medicare Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |